Breast Cancer

TAILORx: How to Apply This Landmark Study

TAILORx changes the configuration of the ball field and the shape of the ball in deciding which women will be recommended chemotherapy after resection of node-negative...

Issues in Oncology

Real-World Evidence Gaining Credibility and Practicality in Treatment Evaluation

In a Friends of Cancer Research (Friends) meeting devoted to real-world evidence, members of the cancer community generally agreed that its use has an increasingly important role to play...

 

Hematologic Malignancies
Leukemia

FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia

On July 20, 2018, the U.S. Food and Drug Administration approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation...

 


Advertisement
Lung Cancer

Durvalumab After Chemoradiation in Unresectable Stage III NSCLC

Early in 2018, durvalumab (Imfinzi) was approved for the treatment of unresectable stage III non–small cell lung cancer (NSCLC) that has not progressed following concurrent platinum-based chemotherapy...

 

Prostate Cancer

Enzalutamide Prolongs Metastasis-Free Survival in Patients With Nonmetastatic, Castration-Resistant Prostate Cancer

As reported in The New England Journal of Medicine by Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, and colleagues, the phase III PROSPER...

 

Advertisement




More Top Stories

Gynecologic Cancers

Kathleen N. Moore, MD, on Ovarian Cancer: Results From the QUADRA Study

Solid Tumors

NCCN Announces New Patient Guideline in Liver, Gallbladder, and Bile Duct Cancers

The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients with liver, gallbladder, and bile duct cancers better understand their diagnosis and treatment options. This new edition of the NCCN Guidelines for Patients® takes the evidence-based, expert consensus...

Advertisement

FDA Grants Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis

iCAD has announced U.S. Food and Drug Administration (FDA) clearance of its artificial intelligence software program, PowerLook Density Assessment Version 3.4, which provides an automated method of determining breast density. The software is compatible with iCAD’s digital breast...

Issues in Oncology

R. Gregory Bociek, MD, on Ethical Considerations of Cancer Treatment

Lung Cancer

Durvalumab After Chemoradiation in Unresectable Stage III NSCLC

Early in 2018, durvalumab (Imfinzi) was approved for the treatment of unresectable stage III non–small cell lung cancer (NSCLC) that has not progressed following concurrent platinum-based chemotherapy and radiation therapy.1,2 Supporting Efficacy Data Approval was based on a planned interim...

Academic Oncology and Industry Offer the Best of Both Worlds for Mace L. Rothenberg, MD

GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed Mace L. Rothenberg, MD,...

Definitive Pelvic Radiation Therapy Plus Chemotherapy and Survival in Newly Diagnosed Metastatic Cervical Cancer

In a study using National Cancer Database data reported in JAMA Oncology, Wang et al found that definitive pelvic radiation therapy plus chemotherapy was associated with improved survival vs chemotherapy alone in newly diagnosed metastatic cervical cancer. The study included data from 3,169...

Prostate Cancer

Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men

St. Baldrick’s Foundation Announces 2018 Summer Grant Recipients

The St. Baldrick’s Foundation has announced its 2018 summer grant recipients, including seven from Baylor College of Medicine and Texas Children’s Cancer and Hematology Centers. 2018 Recipients Nmazou Ozuah, MD, Assistant Professor of Pediatrics, received an international scholar grant for...

Advertisement

Impact of Peer-Review Intervention on Radiotherapy Schedules for Palliative Treatment of Bone Metastases

In a single-center study reported in the Journal of Oncology Practice, Walker et al found that institution of a peer-review process resulted in shorter fractionation schedules for palliation of bone metastases, consistent with current guidelines. As stated by the authors, “Shorter...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.